title: GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype.
abstract: In the search for drugs against schizophrenia and depression without extrapyramidal side effects, compounds that selectively antagonize the dopamine D3 receptor subtype are thought to be a solution. In order to create a model with which the D3 activity can be predicted and that can generate new ideas for future synthesis, we performed a comparative molecular field analysis (CoMFA). In our model 30 ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 25110 to 784. A Q2 of 0.65 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3D contour plots, ideas for the synthesis of new compounds can be generated.
authors.affiliation: Department of Medicinal Chemistry, University Centre for Pharmacy, Groningen, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Nilsson
authors.forename: H
authors.initials: H
authors.lastname: Wikström
authors.forename: A
authors.initials: A
authors.lastname: Smilde
authors.forename: S
authors.initials: S
authors.lastname: Glase
authors.forename: T
authors.initials: T
authors.lastname: Pugsley
authors.forename: G
authors.initials: G
authors.lastname: Cruciani
authors.forename: M
authors.initials: M
authors.lastname: Pastor
authors.forename: S
authors.initials: S
authors.lastname: Clementi
mesh_terms: D000465:Algorithms; D000818:Animals; D001549:Benzamides / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D001667:Binding, Competitive; D016466:CHO Cells; D003198:Computer Simulation; D003201:Computers; D006224:Cricetinae; D018492:Dopamine Antagonists / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D015195:Drug Design; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D009281:Naphthalenes / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3; D012984:Software; D013134:Spiperone / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D001549:Benzamides; C493593:DRD3 protein, human; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D009281:Naphthalenes; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013134:Spiperone